Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes.
- 8 June 2005
- journal article
- Published by Wiley in Liver International
- Vol. 25 (4), 796-807
- https://doi.org/10.1111/j.1478-3231.2005.01098.x
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Hepatocyte growth factor gene therapy accelerates regeneration in cirrhotic mouse livers after hepatectomyGut, 2003
- Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the ratGastroenterology, 2003
- Liver Cirrhosis Is Reverted by Urokinase-Type Plasminogen Activator Gene TherapyMolecular Therapy, 2000
- Gene therapy of hepatic diseases: prospects for the new millenniumGut, 2000
- Gene therapy for hepatic fibrosis?bringing treatment into the new millenniumHepatology, 1999
- Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the ratProceedings of the National Academy of Sciences of the United States of America, 1999
- Hepatocyte growth factor gene therapy of liver cirrhosis in ratsNature Medicine, 1999
- Hepatocyte growth factor: a multifunctional cytokineThe Lancet, 1995
- The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment StrategiesNew England Journal of Medicine, 1993
- THE FINE STRUCTURE, POTASSIUM CONTENT, AND RESPIRATORY ACTIVITY OF ISOLATED RAT LIVER PARENCHYMAL CELLS PREPARED BY IMPROVED ENZYMATIC TECHNIQUESThe Journal of cell biology, 1973